Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Alcohol-mediated behaviou… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1

Forskningsöversiktsartikel
Författare Elisabeth Jerlhag
Publicerad i Brain Research
Volym 1727
ISSN 0006-8993
Publiceringsår 2020
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Språk en
Länkar dx.doi.org/10.1016/j.brainres.2019....
Ämnesord Addiction, Appetite-regulation, Reinforcement, Dopamine, Ethanol, Endocrine signals, ventral tegmental area, body-weight suppression, glp-1 receptor, agonists, food-intake, nucleus-accumbens, glucagon-like-peptide-1, receptor, optogenetic excitation, energy-expenditure, dopamine release, messenger-rnas, Neurosciences & Neurology
Ämneskategorier Farmakologi, Neurovetenskap

Sammanfattning

The neurochemical mechanisms that regulate development of alcohol use disorder (AUD) are complex, and gut-brain peptides were recently pinpointed as novel modulators. Gut-brain peptides, such as glucagon-like peptide-1 (GLP-1), are well known for their ability to regulate food intake and appetite. GLP-1 also controls glucose homeostasis, which lead to the approval of GLP-1 receptor agonists for treatment of diabetes type II. These pharmacotherapies, including exenatide/exendin-4(Ex4) and liraglutide, have also been tested in various animal modes of AUD. In mice, Ex4 attenuates the acute behavioural responses to alcohol. Rat studies additionally show that Ex4 reduces the intake and the intravenous operant self-administration of alcohol and decreases the motivation to consume alcohol. Further studies established that Ex4 modulates alcohol-mediated behaviours via activation of GLP-1 receptors in reward related areas and an area of the hindbrain. In rodents, liraglutide reduces withdrawal symptoms of alcohol, prevents acute alcohol to activate the mesolimbic dopamine system, and in turn reduces various alcohol drinking behaviours. Supportively, liraglutide decreases alcohol intake in vervet monkeys. Finally, another GLP-1 receptor agonist, AC3174, counteracts relapse drinking to alcohol. Of clinical relevance is the case-control study which reveals associations between polymorphisms in the GLP-1 receptor gene and AUD. Furthermore, a polymorphism in the GLP-1 receptor gene is associated with enhanced intravenous self-administration of alcohol in social drinkers and higher response in globus pallidus following high monetary reward. Collectively, these data provide evidence that up-coming clinical trials should evaluate the effect of these GLP-1 receptor agonists on alcohol intake in patients with AUD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?